Clinical Trial Search

Primary: Change Form Baseline Total Sperm Count — 20 10^6 sperm cells/ejaculate

Primary: WT1 T-cell Immune Response (IR) 12-14 Weeks After First GPS Administration (6 x Administrations) — 9 Participants

Primary: Percent of Patients That Complete the Protocol — 61.5; 83.3; 0 percentage of completed patients

Primary: Effect Size of Change From Baseline Caregiving Mastery at 4 Weeks — -0.04 score on a scale

Primary: Number of Participants With Total Cardiovascular Disease (CVD) Events — 410; 456; 429; 437 Participants

Primary: Change From Baseline to 12 Months Post-injection in Mean WOMAC LK3.1 Pain Score in Both Arms of the Study (nSTRIDE APS and Synvisc One) — 11.5; 11.9; 6.7; 7.2 score on a…

Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Defined as the Percentage of Participants With the Antibody Against Anti-PRP — 100.0; 96.2; 94.0…

Primary: Changes in Thalamocortical Functional Connectivity (FC) — 18.2; 17.3 a.u.

Primary: Primary Efficacy: Berg Balance Scale (BBS) — 33.6; 37.3; 42.0 score on a scale — p=0.0002

Primary: Change From Baseline Diabetic Neuropathy Symptoms at 8-weeks — 5.3; 6.2 units on a scale

Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 2079.286; 15197.143 picogram/milliliter (pg/mL)

Primary: Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical…

Primary: Physician Global Assessment (PGA) Score of Clear/Almost Clear — 100; 129; 47; 58 Participants — p=<0.001

Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted Conditions — 122.2406; 122.1489…

Primary: Acceptability as Measured by the System Usability Scale — 80.63; 76.54 scores on a scale